|
US20130072665A1
(en)
*
|
2007-08-23 |
2013-03-21 |
Simon Mark Jackson |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
|
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
|
WO2010151792A1
(en)
|
2009-06-26 |
2010-12-29 |
Regeneron Pharmaceuticals, Inc. |
Readily isolated bispecific antibodies with native immunoglobulin format
|
|
EP2517556B2
(en)
|
2009-07-08 |
2023-03-22 |
Kymab Limited |
Site-Specific Recombination Method, Rodents & Rodent Cells capable of Expressing Chimaeric Antibodies or Chains
|
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
US8518405B2
(en)
|
2009-10-08 |
2013-08-27 |
The University Of North Carolina At Charlotte |
Tumor specific antibodies and uses therefor
|
|
CA2777542A1
(en)
|
2009-10-30 |
2011-05-05 |
Merck Sharp & Dohme Corp. |
Ax213 and ax132 pcsk9 antagonists and variants
|
|
AR079336A1
(es)
|
2009-12-11 |
2012-01-18 |
Irm Llc |
Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
|
|
JO3274B1
(ar)
|
2009-12-24 |
2018-09-16 |
Regeneron Pharma |
أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
|
|
SG183867A1
(en)
*
|
2010-03-11 |
2012-10-30 |
Rinat Neuroscience Corp |
ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
|
|
SG187682A1
(en)
*
|
2010-08-02 |
2013-03-28 |
Macrogenics Inc |
Covalent diabodies and uses thereof
|
|
US9845362B2
(en)
|
2010-10-08 |
2017-12-19 |
The University Of North Carolina At Charlotte |
Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
|
|
JO3756B1
(ar)
|
2010-11-23 |
2021-01-31 |
Regeneron Pharma |
اجسام مضادة بشرية لمستقبلات الجلوكاجون
|
|
MX2013007168A
(es)
*
|
2010-12-22 |
2013-11-04 |
Genentech Inc |
Anticuerpo anti-pcsk9 y metodos de uso.
|
|
EP2481758A1
(en)
*
|
2011-01-28 |
2012-08-01 |
Sanofi |
Human antibodies to PSCK9 for use in methods of treating particular groups of subjects (11566)
|
|
EP2650016A1
(en)
|
2011-01-28 |
2013-10-16 |
Sanofi |
Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565)
|
|
WO2012101252A2
(en)
|
2011-01-28 |
2012-08-02 |
Sanofi |
Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
|
|
EP2679681B2
(en)
|
2011-02-25 |
2023-11-15 |
Chugai Seiyaku Kabushiki Kaisha |
FcgammaRIIB-specific FC antibody
|
|
US8337530B2
(en)
*
|
2011-03-09 |
2012-12-25 |
Zimmer Spine, Inc. |
Polyaxial pedicle screw with increased angulation
|
|
AR088782A1
(es)
|
2011-04-29 |
2014-07-10 |
Sanofi Sa |
Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes
|
|
JOP20200043A1
(ar)
*
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
|
LT2718320T
(lt)
|
2011-06-10 |
2018-04-10 |
Medimmune Limited |
Anti-pseodomonas psl surišančios molekulės ir jų panaudojimas
|
|
JO3412B1
(ar)
|
2011-06-17 |
2019-10-20 |
Regeneron Pharma |
أجسام مضادة ل angptl3 واستخداماتها
|
|
EP2728002B1
(en)
|
2011-06-30 |
2022-01-19 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimerized polypeptide
|
|
CA2840482C
(en)
*
|
2011-07-14 |
2018-10-16 |
Pfizer Inc. |
Treatment with anti-pcsk9 antibodies
|
|
AR087305A1
(es)
*
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
|
EP2756004B1
(en)
|
2011-09-16 |
2019-12-25 |
Regeneron Pharmaceuticals, Inc. |
INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) FOR USE IN REDUCING LIPOPROTEIN(a) LEVELS
|
|
AR087715A1
(es)
*
|
2011-09-16 |
2014-04-09 |
Lilly Co Eli |
Anticuerpos anti pcsk9 y usos de los mismos
|
|
CA2846319A1
(en)
|
2011-09-19 |
2013-03-28 |
Kymab Limited |
Antibodies, variable domains & chains tailored for human use
|
|
EP2761008A1
(en)
|
2011-09-26 |
2014-08-06 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
|
ITPC20110013U1
(it)
|
2011-10-07 |
2013-04-08 |
Giovanni Merli |
Struttura di protezione superiore veicoli.
|
|
MX374826B
(es)
*
|
2011-11-07 |
2025-03-06 |
Medimmune Llc |
Un anticuerpo biespecífico que se une a pcrv y psl de pseudomonas.
|
|
KR20230143201A
(ko)
|
2011-11-30 |
2023-10-11 |
추가이 세이야쿠 가부시키가이샤 |
면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
|
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
CA2858572C
(en)
|
2011-12-08 |
2023-01-17 |
Amgen Inc. |
Human lcat antigen binding proteins and their use in therapy
|
|
JO3533B1
(ar)
|
2012-01-23 |
2020-07-05 |
Regeneron Pharma |
تركيبات ثابته تحتوي على مضادات حيوية مقاومة لـ ang2
|
|
MY168748A
(en)
*
|
2012-01-31 |
2018-11-30 |
Regeneron Pharma |
Anti-asic1 antibodies and uses thereof
|
|
AU2013204581B2
(en)
|
2012-03-16 |
2015-06-25 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals expressing pH-sensitive immunoglobulin sequences
|
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
|
RU2644684C2
(ru)
|
2012-03-16 |
2018-02-13 |
Регенерон Фармасьютикалз, Инк. |
Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения
|
|
HUE045537T2
(hu)
|
2012-03-16 |
2019-12-30 |
Regeneron Pharma |
PH-érzékeny immunglobulin-szekvenciákat expresszáló rágcsálók
|
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
US20130281355A1
(en)
*
|
2012-04-24 |
2013-10-24 |
Genentech, Inc. |
Cell culture compositions and methods for polypeptide production
|
|
EA039663B1
(ru)
*
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
|
US9255154B2
(en)
|
2012-05-08 |
2016-02-09 |
Alderbio Holdings, Llc |
Anti-PCSK9 antibodies and use thereof
|
|
CA2875096A1
(en)
*
|
2012-06-15 |
2013-12-19 |
Genentech, Inc. |
Anti-pcsk9 antibodies, formulations, dosing, and methods of use
|
|
TWI596115B
(zh)
*
|
2012-08-13 |
2017-08-21 |
再生元醫藥公司 |
具有ｐＨ－依賴性結合特性之抗－ＰＣＳＫ９抗體
|
|
JO3462B1
(ar)
|
2012-08-22 |
2020-07-05 |
Regeneron Pharma |
أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
|
|
TWI855488B
(zh)
|
2012-08-24 |
2024-09-11 |
日商中外製藥股份有限公司 |
FcγRIIb特異性Fc區域變異體
|
|
EP2703009A1
(en)
|
2012-08-31 |
2014-03-05 |
Sanofi |
Combination treatments involving antibodies to human PCSK9
|
|
EP2703008A1
(en)
*
|
2012-08-31 |
2014-03-05 |
Sanofi |
Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
|
|
EP2706070A1
(en)
|
2012-09-06 |
2014-03-12 |
Sanofi |
Combination treatments involving antibodies to human PCSK9
|
|
US12115341B2
(en)
|
2012-11-21 |
2024-10-15 |
Amgen Inc. |
Drug delivery device
|
|
CN105102618B
(zh)
|
2012-12-27 |
2018-04-17 |
中外制药株式会社 |
异源二聚化多肽
|
|
US20150335615A1
(en)
*
|
2013-01-04 |
2015-11-26 |
Toshihisa Kawai |
Cholesterol-lowering compounds in combination with lipid metabolism-altering compounds of non-absorbable sugars, compounds that convert nh3 to nh4+, or hydrogen-generating compounds for the treatment of high cholesterol and inflammation
|
|
WO2014107739A1
(en)
*
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
|
WO2014149699A1
(en)
|
2013-03-15 |
2014-09-25 |
Eli Lilly And Company |
Bifunctional protein
|
|
WO2014144096A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Drug cassette, autoinjector, and autoinjector system
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
CA2906508A1
(en)
*
|
2013-03-15 |
2014-09-25 |
Amgen, Inc. |
Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
|
|
CA2903495C
(en)
|
2013-03-15 |
2021-05-25 |
Amgen Inc. |
Body contour adaptable autoinjector device
|
|
TWI639449B
(zh)
|
2013-03-15 |
2018-11-01 |
美商安美基公司 |
用於注射器之匣盒
|
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
BR112015024282B1
(pt)
|
2013-03-22 |
2022-05-17 |
Amgen Inc |
Injetor e método de montagem do injetor
|
|
US11267868B2
(en)
|
2013-04-02 |
2022-03-08 |
Chugai Seiyaku Kabushiki Kaisha |
Fc region variant
|
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
TWI682780B
(zh)
*
|
2013-05-30 |
2020-01-21 |
美商再生元醫藥公司 |
醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
|
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
|
EP2810955A1
(en)
|
2013-06-07 |
2014-12-10 |
Sanofi |
Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
|
|
ES2901400T3
(es)
*
|
2013-06-07 |
2022-03-22 |
Regeneron Pharma |
Métodos para inhibir la ateroesclerosis administrando un inhibidor de PCSK9
|
|
EP2862877A1
(en)
|
2013-10-18 |
2015-04-22 |
Sanofi |
Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
|
|
EA201592267A1
(ru)
|
2013-06-07 |
2016-04-29 |
Ридженерон Фармасьютикалз, Инк. |
Способы ингибирования атеросклероза посредством введения ингибитора pcsk9
|
|
AU2013396206B2
(en)
|
2013-06-28 |
2019-11-14 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolemia
|
|
ES2993142T3
(en)
|
2013-10-01 |
2024-12-23 |
Kymab Ltd |
Animal models and therapeutic molecules
|
|
EA037526B1
(ru)
*
|
2013-10-11 |
2021-04-08 |
Санофи Байотекнолоджи |
Применение ингибитора pcsk9 для лечения гиперлипидемии
|
|
CA2926110C
(en)
|
2013-10-24 |
2023-05-23 |
Amgen Inc. |
Drug delivery system with temperature-sensitive control
|
|
WO2015061386A1
(en)
|
2013-10-24 |
2015-04-30 |
Amgen Inc. |
Injector and method of assembly
|
|
ES2864350T3
(es)
*
|
2013-11-12 |
2021-10-13 |
Regeneron Pharma |
Pautas posológicas para uso con inhibidores de PCSK9
|
|
EA201690889A1
(ru)
|
2013-11-12 |
2016-11-30 |
Санофи Байотекнолоджи |
Режимы дозирования для применения ингибиторов pcsk9
|
|
US8945560B1
(en)
|
2014-07-15 |
2015-02-03 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
|
US8883157B1
(en)
|
2013-12-17 |
2014-11-11 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9017678B1
(en)
|
2014-07-15 |
2015-04-28 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
|
US9023359B1
(en)
|
2014-07-15 |
2015-05-05 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9034332B1
(en)
|
2014-07-15 |
2015-05-19 |
Kymab Limited |
Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9051378B1
(en)
|
2014-07-15 |
2015-06-09 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
|
DE202014010499U1
(de)
|
2013-12-17 |
2015-10-20 |
Kymab Limited |
Targeting von humaner PCSK9 zur Cholesterinbehandlung
|
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
|
ES2729057T3
(es)
*
|
2013-12-17 |
2019-10-30 |
Aimm Therapeutics Bv |
Medios y métodos para contrarrestar trastornos mieloproliferativos o linfoproliferativos
|
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
US9045548B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
US10994112B2
(en)
|
2014-02-05 |
2021-05-04 |
Amgen Inc. |
Drug delivery system with electromagnetic field generator
|
|
CA2939507A1
(en)
|
2014-02-14 |
2015-08-20 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
CN106794244A
(zh)
*
|
2014-03-17 |
2017-05-31 |
赛诺菲生物技术公司 |
用于降低心血管风险的方法
|
|
EP3785749A1
(en)
|
2014-05-07 |
2021-03-03 |
Amgen Inc. |
Autoinjector with shock reducing elements
|
|
CN106459960A
(zh)
|
2014-05-13 |
2017-02-22 |
生物蛋白有限公司 |
条件活性生物蛋白
|
|
MX2016015926A
(es)
|
2014-06-03 |
2017-06-26 |
Amgen Inc |
Sistema de suministro de farmacos y metodo de uso.
|
|
WO2015200438A1
(en)
*
|
2014-06-24 |
2015-12-30 |
Eleven Biotherapeutics, Inc. |
High affinity antibodies against pcsk9
|
|
US9150660B1
(en)
|
2014-07-15 |
2015-10-06 |
Kymab Limited |
Precision Medicine by targeting human NAV1.8 variants for treatment of pain
|
|
EP2975059A1
(en)
|
2014-07-15 |
2016-01-20 |
Kymab Limited |
Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
|
|
DE202015009006U1
(de)
|
2014-07-15 |
2016-08-19 |
Kymab Limited |
Targeting von humaner PCSK9 zur Cholesterinbehandlung
|
|
EP4328245A3
(en)
|
2014-07-15 |
2024-06-05 |
Kymab Ltd. |
Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
|
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
|
PL3169353T3
(pl)
*
|
2014-07-16 |
2020-06-01 |
Sanofi Biotechnology |
SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH)
|
|
AU2015289617B2
(en)
|
2014-07-16 |
2021-04-15 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating high cardiovascular risk patients with hypercholesterolemia
|
|
AR101262A1
(es)
|
2014-07-26 |
2016-12-07 |
Regeneron Pharma |
Plataforma de purificación para anticuerpos biespecíficos
|
|
CA2956991A1
(en)
|
2014-08-06 |
2016-02-11 |
Rinat Neuroscience Corp. |
Methods for reducing ldl-cholesterol
|
|
WO2016020799A1
(en)
|
2014-08-06 |
2016-02-11 |
Rinat Neuroscience Corp. |
Methods for reducing ldl-cholesterol
|
|
WO2016023916A1
(en)
|
2014-08-12 |
2016-02-18 |
Kymab Limited |
Treatment of disease using ligand binding to targets of interest
|
|
US11554181B2
(en)
|
2014-09-05 |
2023-01-17 |
The University Of North Carolina At Charlotte |
Tumor specific antibody conjugates and uses therefor
|
|
CA2960763A1
(en)
|
2014-09-16 |
2016-03-24 |
Regeneron Pharmaceuticals, Inc. |
Anti-glucagon antibodies and uses thereof
|
|
EP3197492A1
(en)
|
2014-09-23 |
2017-08-02 |
Pfizer Inc |
Treatment with anti-pcsk9 antibodies
|
|
MX392725B
(es)
|
2014-10-14 |
2025-03-24 |
Amgen Inc |
Dispositivo de inyeccion de farmaco con indicadores visuales y audibles.
|
|
BR112017008125B1
(pt)
|
2014-10-23 |
2023-11-21 |
Amgen Inc. |
Método para a redução da viscosidade de formulações farmacêuticas, formulações farmacêuticas, método de preparação de um pó liofilizado, pó liofilizado e método para reconstituição de um pó liofilizado
|
|
WO2016071701A1
(en)
|
2014-11-07 |
2016-05-12 |
Kymab Limited |
Treatment of disease using ligand binding to targets of interest
|
|
AR103161A1
(es)
|
2014-12-19 |
2017-04-19 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
|
|
EP3848072A1
(en)
|
2014-12-19 |
2021-07-14 |
Amgen Inc. |
Drug delivery device with proximity sensor
|
|
JP2017538512A
(ja)
|
2014-12-19 |
2017-12-28 |
アムジエン・インコーポレーテツド |
ライブボタンまたはユーザインタフェースフィールドを含む薬物送達装置
|
|
TW202248212A
(zh)
|
2015-02-05 |
2022-12-16 |
日商中外製藥股份有限公司 |
包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途
|
|
CN105461809B
(zh)
*
|
2015-02-11 |
2018-10-12 |
康融东方（广东）医药有限公司 |
Pcsk9抗体、其药物组合物及其用途
|
|
US10583245B2
(en)
|
2015-02-17 |
2020-03-10 |
Amgen Inc. |
Drug delivery device with vacuum assisted securement and/or feedback
|
|
JP2018512184A
(ja)
|
2015-02-27 |
2018-05-17 |
アムジエン・インコーポレーテツド |
針ガードの移動に対する抵抗力の閾値が調整可能な針ガード機構を備えた薬物送達装置
|
|
AU2016235662B2
(en)
*
|
2015-03-20 |
2020-07-30 |
Aarhus Universitet |
Inhibitors of PCSK9 for treatment of lipoprotein metabolism disorders
|
|
JP6913030B2
(ja)
|
2015-05-18 |
2021-08-04 |
アジェンシス，インコーポレイテッド |
Ａｘｌタンパク質に結合する抗体
|
|
US10787516B2
(en)
|
2015-05-18 |
2020-09-29 |
Agensys, Inc. |
Antibodies that bind to AXL proteins
|
|
CN106084058B
(zh)
*
|
2015-07-15 |
2019-08-27 |
北京天广实生物技术股份有限公司 |
抗人pcsk9单克隆抗体
|
|
TWI870789B
(zh)
|
2015-08-04 |
2025-01-21 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
|
AU2016308111A1
(en)
|
2015-08-18 |
2018-03-01 |
Regeneron Pharmaceuticals, Inc. |
Anti-PCSK9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
|
|
WO2017039786A1
(en)
|
2015-09-02 |
2017-03-09 |
Amgen Inc. |
Syringe assembly adapter for a syringe
|
|
WO2017055966A1
(en)
|
2015-10-01 |
2017-04-06 |
Pfizer Inc. |
Low viscosity antibody compositions
|
|
CN106589127A
(zh)
|
2015-10-16 |
2017-04-26 |
钜川生物医药 |
一种pcsk9抗体及其制备方法和应用
|
|
CN105348390B
(zh)
*
|
2015-10-26 |
2018-08-28 |
北京智仁美博生物科技有限公司 |
抗人pcsk9单克隆抗体
|
|
CN106810609A
(zh)
*
|
2015-11-27 |
2017-06-09 |
苏州君盟生物医药科技有限公司 |
抗pcsk9抗体及其应用
|
|
WO2017100501A1
(en)
|
2015-12-09 |
2017-06-15 |
Amgen Inc. |
Auto-injector with signaling cap
|
|
EP3394098A4
(en)
|
2015-12-25 |
2019-11-13 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
|
|
CA3009904A1
(en)
*
|
2015-12-31 |
2017-07-06 |
Jiangsu Hengrui Medicine Co., Ltd. |
Pcsk9 antibody, antigen-binding fragment thereof, and medicinal application thereof
|
|
WO2017120178A1
(en)
|
2016-01-06 |
2017-07-13 |
Amgen Inc. |
Auto-injector with signaling electronics
|
|
IL260931B2
(en)
*
|
2016-02-17 |
2024-09-01 |
Regeneron Pharma |
Methods of treating or preventing atherosclerosis by blocking ANGPTL3
|
|
WO2017151783A1
(en)
|
2016-03-03 |
2017-09-08 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor
|
|
US11200298B2
(en)
|
2016-03-15 |
2021-12-14 |
Amgen Inc. |
Reducing probability of glass breakage in drug delivery devices
|
|
US11066464B2
(en)
|
2016-03-21 |
2021-07-20 |
Kymab Limited |
Anti-malarial antibodies that bind circumsporozoite protein
|
|
WO2017163049A1
(en)
|
2016-03-21 |
2017-09-28 |
Kymab Limited |
Anti-malarial antibodies that bind circumsporozoite protein
|
|
CN107266575B
(zh)
*
|
2016-04-07 |
2021-12-24 |
天士力生物医药股份有限公司 |
前蛋白转化酶枯草溶菌素kexin 9型的结合蛋白及其应用
|
|
WO2017189089A1
(en)
|
2016-04-29 |
2017-11-02 |
Amgen Inc. |
Drug delivery device with messaging label
|
|
WO2017192287A1
(en)
|
2016-05-02 |
2017-11-09 |
Amgen Inc. |
Syringe adapter and guide for filling an on-body injector
|
|
ES2959783T3
(es)
|
2016-05-13 |
2024-02-28 |
Amgen Inc |
Conjunto de cubierta protectora de vial
|
|
WO2017200989A1
(en)
|
2016-05-16 |
2017-11-23 |
Amgen Inc. |
Data encryption in medical devices with limited computational capability
|
|
WO2017209899A1
(en)
|
2016-06-03 |
2017-12-07 |
Amgen Inc. |
Impact testing apparatuses and methods for drug delivery devices
|
|
CN107474140B
(zh)
|
2016-06-08 |
2022-06-03 |
常州博嘉生物医药科技有限公司 |
Pcsk9特异性的结合蛋白mv072及其应用
|
|
RU2769282C2
(ru)
|
2016-06-20 |
2022-03-30 |
Кимаб Лимитед |
Анти-PD-L1 и IL-2 цитокины
|
|
WO2018029474A2
(en)
|
2016-08-09 |
2018-02-15 |
Kymab Limited |
Anti-icos antibodies
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
WO2018004842A1
(en)
|
2016-07-01 |
2018-01-04 |
Amgen Inc. |
Drug delivery device having minimized risk of component fracture upon impact events
|
|
EP3487878A4
(en)
*
|
2016-07-20 |
2020-03-25 |
University of Utah Research Foundation |
CAR-T CD229 LYMPHOCYTES AND METHODS OF USE
|
|
EP3494991A4
(en)
|
2016-08-05 |
2020-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
|
|
CA3032897A1
(en)
|
2016-08-09 |
2018-02-15 |
Kymab Limited |
Anti-icos antibodies
|
|
US20190328965A1
(en)
|
2016-08-17 |
2019-10-31 |
Amgen Inc. |
Drug delivery device with placement detection
|
|
EP3504328A1
(en)
|
2016-08-24 |
2019-07-03 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
|
EP3515950A4
(en)
|
2016-09-20 |
2020-10-28 |
Wuxi Biologics Ireland Limited. |
NEW ANTI-PCSK9 ANTIBODIES
|
|
EP3515949A4
(en)
*
|
2016-09-20 |
2020-10-28 |
Wuxi Biologics Ireland Limited. |
NEW ANTI-PCSK9 ANTIBODIES
|
|
US11459401B2
(en)
|
2016-10-06 |
2022-10-04 |
Amgen Inc. |
Reduced viscosity protein pharmaceutical formulations
|
|
WO2018075621A1
(en)
*
|
2016-10-19 |
2018-04-26 |
Vanderbilt University |
Human orthopoxvirus antibodies and methods of use therefor
|
|
WO2018075792A1
(en)
|
2016-10-20 |
2018-04-26 |
Regeneron Pharmaceuticals, Inc. |
Methods of lowering blood glucose levels
|
|
WO2018081234A1
(en)
|
2016-10-25 |
2018-05-03 |
Amgen Inc. |
On-body injector
|
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
JOP20190112A1
(ar)
|
2016-11-14 |
2019-05-14 |
Amgen Inc |
علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
|
|
CN108239150A
(zh)
*
|
2016-12-24 |
2018-07-03 |
信达生物制药(苏州)有限公司 |
抗pcsk9抗体及其用途
|
|
EP3570917A1
(en)
|
2017-01-17 |
2019-11-27 |
Amgen Inc. |
Injection devices and related methods of use and assembly
|
|
CN107698680B
(zh)
*
|
2017-01-22 |
2019-03-01 |
北京东方百泰生物科技有限公司 |
抗pcsk9单克隆抗体
|
|
CN108424457B
(zh)
*
|
2017-02-13 |
2021-06-01 |
成都金洛克锶生物技术有限公司 |
针对pcsk9抗体与检测试剂盒的制备及其用途
|
|
US11369736B2
(en)
|
2017-02-17 |
2022-06-28 |
Amgen Inc. |
Cannula insertion and retraction mechanisms
|
|
MX2019009625A
(es)
|
2017-02-17 |
2019-10-09 |
Amgen Inc |
Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje.
|
|
JP7377596B2
(ja)
|
2017-02-22 |
2023-11-10 |
アムジエン・インコーポレーテツド |
低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
|
|
EP3592403B1
(en)
|
2017-03-06 |
2025-08-20 |
Amgen Inc. |
Drug delivery device with activation prevention feature
|
|
MX2019010543A
(es)
|
2017-03-07 |
2019-10-21 |
Amgen Inc |
Insercion de agujas por sobrepresion.
|
|
JP2020509837A
(ja)
|
2017-03-09 |
2020-04-02 |
アムジエン・インコーポレーテツド |
薬剤送達装置のための挿入機構
|
|
LT3600491T
(lt)
|
2017-03-28 |
2023-10-10 |
Amgen Inc. |
Stūmoklio koto ir švirkšto konstrukcinė sistema ir būdas
|
|
US9989519B1
(en)
*
|
2017-05-04 |
2018-06-05 |
Clayton Pharmaceuticals, LLC |
Method for determining in vitro bioequivalence of a sucralfate suspension sample to a sucralfate suspension reference listed drug (RLD)
|
|
CA3061982A1
(en)
|
2017-06-08 |
2018-12-13 |
Amgen Inc. |
Syringe assembly for a drug delivery device and method of assembly
|
|
EP3634546A1
(en)
|
2017-06-08 |
2020-04-15 |
Amgen Inc. |
Torque driven drug delivery device
|
|
US20190031774A1
(en)
|
2017-06-09 |
2019-01-31 |
Sanofi Biotechnology |
Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
|
|
TW201904608A
(zh)
*
|
2017-06-09 |
2019-02-01 |
法商賽諾菲生物技術公司 |
藉由投予ｐｃｓｋ９抑制劑治療糖尿病患者高血脂症之方法
|
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
|
JP7195276B2
(ja)
|
2017-06-22 |
2022-12-23 |
アムジエン・インコーポレーテツド |
デバイス起動による衝突／衝撃の低減
|
|
MX2019015479A
(es)
|
2017-06-23 |
2020-02-20 |
Amgen Inc |
Dispositivo electronico de administracion de farmacos con tapa accionada por un conjunto de conmutador.
|
|
MX2020000228A
(es)
|
2017-07-06 |
2020-08-10 |
Regeneron Pharma |
Proceso de cultivo celular para producir una glicoproteina.
|
|
ES2972207T3
(es)
|
2017-07-14 |
2024-06-11 |
Amgen Inc |
Sistema de inserción-retracción de agujas con sistema de resorte de torsión doble
|
|
US11672733B2
(en)
|
2017-07-21 |
2023-06-13 |
Amgen Inc. |
Gas permeable sealing member for drug container and methods of assembly
|
|
EP3658203B2
(en)
|
2017-07-25 |
2025-10-01 |
Amgen Inc. |
Drug delivery device with gear module and related method of assembly
|
|
JP7242562B2
(ja)
|
2017-07-25 |
2023-03-20 |
アムジエン・インコーポレーテツド |
容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法
|
|
WO2019032482A2
(en)
|
2017-08-09 |
2019-02-14 |
Amgen Inc. |
HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM
|
|
US11077246B2
(en)
|
2017-08-18 |
2021-08-03 |
Amgen Inc. |
Wearable injector with sterile adhesive patch
|
|
US11103636B2
(en)
|
2017-08-22 |
2021-08-31 |
Amgen Inc. |
Needle insertion mechanism for drug delivery device
|
|
EP3691717B1
(en)
|
2017-10-04 |
2023-02-08 |
Amgen Inc. |
Flow adapter for drug delivery device
|
|
EP4257164A3
(en)
|
2017-10-06 |
2024-01-17 |
Amgen Inc. |
Drug delivery device with interlock assembly and related method of assembly
|
|
EP3694578B1
(en)
|
2017-10-09 |
2025-09-24 |
Amgen Inc. |
Drug delivery device with drive assembly and related method of assembly
|
|
WO2019090079A1
(en)
|
2017-11-03 |
2019-05-09 |
Amgen Inc. |
System and approaches for sterilizing a drug delivery device
|
|
ES2994389T3
(en)
|
2017-11-06 |
2025-01-23 |
Amgen Inc |
Drug delivery device with placement and flow sensing
|
|
MA50569A
(fr)
|
2017-11-06 |
2020-09-16 |
Amgen Inc |
Ensembles de remplissage-finition et procédés associés
|
|
CN111225696B
(zh)
|
2017-11-10 |
2023-07-18 |
安进公司 |
用于药物递送装置的柱塞
|
|
JP7731196B2
(ja)
|
2017-11-14 |
2025-08-29 |
中外製薬株式会社 |
抗Ｃ１ｓ抗体および使用方法
|
|
WO2019099322A1
(en)
|
2017-11-16 |
2019-05-23 |
Amgen Inc. |
Autoinjector with stall and end point detection
|
|
CA3079540A1
(en)
|
2017-11-16 |
2019-05-23 |
Amgen Inc. |
Door latch mechanism for drug delivery device
|
|
US11629189B2
(en)
|
2017-12-19 |
2023-04-18 |
Kymab Limited |
Bispecific antibody for ICOS and PD-L1
|
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
|
CN115925882A
(zh)
|
2017-12-22 |
2023-04-07 |
瑞泽恩制药公司 |
用于表征药物产品杂质的系统和方法
|
|
WO2019152599A1
(en)
*
|
2018-01-31 |
2019-08-08 |
The Wistar Institute Of Anatomy And Biology |
Nucleic acid monoclonal antibodies targeting pcsk9 and methods of use
|
|
CN111655722A
(zh)
|
2018-01-31 |
2020-09-11 |
瑞泽恩制药公司 |
用于表征药物产品杂质的系统和方法
|
|
TWI786265B
(zh)
|
2018-02-02 |
2022-12-11 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
|
US11957745B2
(en)
|
2018-02-22 |
2024-04-16 |
Vanderbilt University |
Human Japanese Encephalitis Virus antibodies and methods of use therefor
|
|
CA3088906A1
(en)
|
2018-02-28 |
2019-09-06 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for identifying viral contaminants
|
|
AU2019231703A1
(en)
|
2018-03-06 |
2020-10-22 |
Regeneron Pharmaceuticals, Inc. |
Use of PCSK9 inhibitor for reducing cardiovascular risk
|
|
CN111868085B
(zh)
|
2018-03-19 |
2024-11-05 |
瑞泽恩制药公司 |
微芯片毛细管电泳测定法及试剂
|
|
US12259355B2
(en)
|
2018-03-19 |
2025-03-25 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
US12253490B2
(en)
|
2018-03-19 |
2025-03-18 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
US10835685B2
(en)
|
2018-05-30 |
2020-11-17 |
Amgen Inc. |
Thermal spring release mechanism for a drug delivery device
|
|
US11083840B2
(en)
|
2018-06-01 |
2021-08-10 |
Amgen Inc. |
Modular fluid path assemblies for drug delivery devices
|
|
MY208638A
(en)
|
2018-07-02 |
2025-05-21 |
Amgen Inc |
Anti-steap1 antigen-binding protein
|
|
CN112351804A
(zh)
|
2018-07-24 |
2021-02-09 |
安进公司 |
用于施用药物的输送装置
|
|
WO2020023220A1
(en)
|
2018-07-24 |
2020-01-30 |
Amgen Inc. |
Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
|
|
MX2021000748A
(es)
|
2018-07-24 |
2021-03-26 |
Amgen Inc |
Dispositivos de suministro para administrar farmacos.
|
|
US12115360B2
(en)
|
2018-07-24 |
2024-10-15 |
Amgen Inc. |
Hybrid drug delivery devices with grip portion
|
|
CA3103105A1
(en)
|
2018-07-31 |
2020-02-06 |
Amgen Inc. |
Fluid path assembly for a drug delivery device
|
|
CN118754986A
(zh)
|
2018-08-10 |
2024-10-11 |
中外制药株式会社 |
抗cd137抗原结合分子及其应用
|
|
JP2021535739A
(ja)
|
2018-08-27 |
2021-12-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
下流精製でのラマン分光法の使用
|
|
KR20210053816A
(ko)
|
2018-08-30 |
2021-05-12 |
리제너론 파마슈티칼스 인코포레이티드 |
단백질 복합체를 특성화하기 위한 방법
|
|
CN110872353B
(zh)
*
|
2018-09-03 |
2021-05-04 |
深圳华大基因科技有限公司 |
特异性结合pcsk9抗原的纳米抗体及其制备方法和应用
|
|
MA53724A
(fr)
|
2018-09-24 |
2021-12-29 |
Amgen Inc |
Systèmes et procédés de dosage interventionnel
|
|
EP3856283A1
(en)
|
2018-09-28 |
2021-08-04 |
Amgen Inc. |
Muscle wire escapement activation assembly for a drug delivery device
|
|
TWI857975B
(zh)
|
2018-10-02 |
2024-10-11 |
美商安進公司 |
具有內部力傳遞的用於藥物遞送之注射系統
|
|
MX2021003491A
(es)
|
2018-10-05 |
2021-06-18 |
Amgen Inc |
Dispositivo de administracion de farmacos con indicador de dosis.
|
|
EA202191038A1
(ru)
|
2018-10-15 |
2021-07-06 |
Эмджен Инк. |
Способ платформенной сборки для устройства доставки лекарственного средства
|
|
EP3866890A1
(en)
|
2018-10-15 |
2021-08-25 |
Amgen Inc. |
Drug delivery device having damping mechanism
|
|
CN111110841A
(zh)
*
|
2018-10-31 |
2020-05-08 |
上海君实生物医药科技股份有限公司 |
含有抗pcsk9抗体的稳定制剂
|
|
BR112021008355A2
(pt)
*
|
2018-10-31 |
2021-08-03 |
Delinia, Inc. |
moduladores de célula t regulatória multivalente
|
|
TWI831847B
(zh)
|
2018-11-01 |
2024-02-11 |
美商安進公司 |
部分針頭縮回之藥物遞送裝置及其操作方法
|
|
US11213620B2
(en)
|
2018-11-01 |
2022-01-04 |
Amgen Inc. |
Drug delivery devices with partial drug delivery member retraction
|
|
EP3873563A1
(en)
|
2018-11-01 |
2021-09-08 |
Amgen Inc. |
Drug delivery devices with partial drug delivery member retraction
|
|
GB201820687D0
(en)
|
2018-12-19 |
2019-01-30 |
Kymab Ltd |
Antagonists
|
|
EP4220173A3
(en)
|
2019-01-16 |
2023-10-18 |
Regeneron Pharmaceuticals, Inc. |
Methods for characterizing disulfide bonds
|
|
CN109734813B
(zh)
*
|
2019-01-28 |
2022-06-17 |
广东昭泰体内生物医药科技有限公司 |
一种嵌合抗原受体及其应用
|
|
JP7510952B2
(ja)
|
2019-04-24 |
2024-07-04 |
アムジエン・インコーポレーテツド |
シリンジ滅菌確認アセンブリ及び方法
|
|
KR20220007586A
(ko)
|
2019-05-13 |
2022-01-18 |
리제너론 파마슈티칼스 인코포레이티드 |
개선된 경쟁적 리간드 결합 검정
|
|
WO2020230834A1
(en)
|
2019-05-15 |
2020-11-19 |
Chugai Seiyaku Kabushiki Kaisha |
An antigen-binding molecule, a pharmaceutical composition, and a method
|
|
US12264366B2
(en)
|
2019-05-17 |
2025-04-01 |
Regeneron Pharmaceuticals, Inc. |
Genome-based methods for reducing cardiovascular risk
|
|
AU2020337250A1
(en)
|
2019-08-23 |
2022-03-03 |
Amgen Inc. |
Drug delivery device with configurable needle shield engagement components and related methods
|
|
WO2021058597A1
(en)
|
2019-09-24 |
2021-04-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of determining whether a subject is at risk of developing arterial plaques
|
|
KR20220066393A
(ko)
|
2019-09-24 |
2022-05-24 |
리제너론 파아마슈티컬스, 인크. |
크로마토그래피의 사용 및 재생을 위한 시스템 및 방법
|
|
US12297451B1
(en)
|
2019-10-25 |
2025-05-13 |
Regeneron Pharmaceuticals, Inc. |
Cell culture medium
|
|
AU2020394428B2
(en)
|
2019-11-25 |
2025-11-20 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous emulsions
|
|
CN115066272A
(zh)
|
2019-12-10 |
2022-09-16 |
再生元制药公司 |
Pcsk9抑制剂治疗纯合家族性高胆固醇血症的用途
|
|
AU2021209866B2
(en)
|
2020-01-21 |
2023-07-06 |
Regeneron Pharmaceuticals, Inc. |
Deglycosylation methods for electrophoresis of glycosylated proteins
|
|
JP7765457B2
(ja)
*
|
2020-08-06 |
2025-11-06 |
ステレクシス セラピューティクス，エルエルシー |
Ｉｌ－８抗体及びその使用方法
|
|
MX2023002417A
(es)
|
2020-08-31 |
2023-03-22 |
Regeneron Pharma |
Estrategias de suministro de asparagina para mejorar el rendimiento del cultivo celular y mitigar las variantes de secuencia de asparagina.
|
|
IL303027A
(en)
|
2020-11-25 |
2023-07-01 |
Regeneron Pharma |
Sustained release formulations by creating a non-aqueous membrane emulsion
|
|
EP4262757A1
(en)
|
2020-12-17 |
2023-10-25 |
Regeneron Pharmaceuticals, Inc. |
Fabrication of protein-encapsulating microgels
|
|
JP2024503408A
(ja)
|
2021-01-20 |
2024-01-25 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
細胞培養におけるタンパク質力価の改善方法
|
|
AU2022230987A1
(en)
|
2021-03-03 |
2023-08-31 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for quantifying and modifying protein viscosity
|
|
AU2022243005A1
(en)
|
2021-03-26 |
2023-10-05 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for developing mixing protocols
|
|
CA3219336A1
(en)
|
2021-05-18 |
2022-11-24 |
Kymab Limited |
Uses of anti-icos antibodies
|
|
BR112023024278A2
(pt)
|
2021-05-21 |
2024-01-30 |
Amgen Inc |
Método de otimizar uma receita de enchimento para um recipiente de fármacos
|
|
EP4348234A1
(en)
|
2021-06-01 |
2024-04-10 |
Regeneron Pharmaceuticals, Inc. |
Micropchip capillary electrophoresis assays and reagents
|
|
GB202107994D0
(en)
|
2021-06-04 |
2021-07-21 |
Kymab Ltd |
Treatment of cancer
|
|
EP4367134A1
(en)
|
2021-07-05 |
2024-05-15 |
Regeneron Pharmaceuticals, Inc. |
Utilization of antibodies to shape antibody responses to an antigen
|
|
AR127006A1
(es)
|
2021-09-08 |
2023-12-06 |
Regeneron Pharma |
UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc
|
|
KR20240058201A
(ko)
|
2021-09-20 |
2024-05-03 |
리제너론 파마슈티칼스 인코포레이티드 |
항체 이질성을 제어하는 방법
|
|
WO2023059800A2
(en)
|
2021-10-07 |
2023-04-13 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods of ph modeling and control
|
|
CN118076885A
(zh)
|
2021-10-07 |
2024-05-24 |
里珍纳龙药品有限公司 |
pH计校准与校正
|
|
WO2023076340A1
(en)
|
2021-10-26 |
2023-05-04 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
|
|
TW202346856A
(zh)
|
2022-03-18 |
2023-12-01 |
美商里珍納龍藥品有限公司 |
分析多肽變體的方法及系統
|
|
EP4525991A1
(en)
|
2022-05-18 |
2025-03-26 |
Kymab Limited |
Uses of anti-icos antibodies
|
|
EP4573553A1
(en)
|
2022-08-15 |
2025-06-25 |
ABSCI Corporation |
Quantitative affinity activity specific cell enrichment
|
|
CN120418653A
(zh)
|
2022-12-16 |
2025-08-01 |
里珍纳龙药品有限公司 |
评估色谱柱完整性的方法和系统
|
|
WO2024130165A1
(en)
|
2022-12-16 |
2024-06-20 |
Regeneron Pharmaceuticals, Inc. |
Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome
|
|
EP4655595A1
(en)
|
2023-01-25 |
2025-12-03 |
Regeneron Pharmaceuticals, Inc. |
Mass spectrometry-based characterization of antibodies co-expressed in vivo
|
|
TW202445135A
(zh)
|
2023-01-25 |
2024-11-16 |
美商再生元醫藥公司 |
液態蛋白質組成物穩定性之建模方法
|
|
TW202445138A
(zh)
|
2023-02-01 |
2024-11-16 |
美商再生元醫藥公司 |
用於生物巨分子分析之具質譜法的不對稱流場流分離
|
|
EP4669963A2
(en)
|
2023-02-22 |
2025-12-31 |
Regeneron Pharmaceuticals, Inc. |
SYSTEM FITNESS PARAMETERS AND COLUMN AGING
|
|
AU2024265540A1
(en)
|
2023-05-01 |
2025-10-30 |
Regeneron Pharmaceuticals, Inc. |
Multidose antibody drug products using phenol or benzyl alcohol
|
|
EP4467563A1
(en)
*
|
2023-05-23 |
2024-11-27 |
JLP Health GmbH |
Ldlr derived polypeptides for anti-viral uses
|
|
WO2024240848A1
(en)
*
|
2023-05-23 |
2024-11-28 |
Jlp Health Gmbh |
Ldlr derived polypeptides for anti-viral uses
|
|
US20250086164A1
(en)
|
2023-09-08 |
2025-03-13 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for assessing chromatographic column integrity
|
|
WO2025064403A2
(en)
|
2023-09-18 |
2025-03-27 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for developing chromatography protocols
|
|
TW202532098A
(zh)
|
2023-09-29 |
2025-08-16 |
美商再生元醫藥公司 |
使用控制成核之冷凍乾燥
|
|
WO2025085594A1
(en)
|
2023-10-18 |
2025-04-24 |
Regeneron Pharmaceuticals, Inc. |
Rapid purification of monoclonal antibody from in-process upstream cell culture material
|
|
TW202535934A
(zh)
|
2023-11-02 |
2025-09-16 |
美商再生元醫藥公司 |
利用應力來降低脂酶活性的方法
|
|
WO2025144700A1
(en)
|
2023-12-27 |
2025-07-03 |
Absci Corporation |
Nanobody library screening using bacterial surface display
|
|
WO2025166281A1
(en)
|
2024-02-01 |
2025-08-07 |
Regeneron Pharmaceuticals, Inc. |
Platform for charge-detection mass spectrometry analysis of aavs
|
|
WO2025175164A1
(en)
|
2024-02-16 |
2025-08-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
|
|
WO2025194043A1
(en)
|
2024-03-15 |
2025-09-18 |
Regeneron Pharmaceuticals, Inc. |
Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
|
|
WO2025259840A1
(en)
|
2024-06-13 |
2025-12-18 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for scaled chromatography
|